SpringWorks Therapeutics (SWTX) Scheduled to Post Earnings on Thursday

SpringWorks Therapeutics (NASDAQ:SWTX) will be issuing its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($1.19) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its earnings results on Tuesday, February 27th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.20). The company had revenue of $5.45 million for the quarter, compared to analyst estimates of $1.26 million. During the same quarter in the prior year, the firm posted ($1.19) earnings per share. On average, analysts expect SpringWorks Therapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SpringWorks Therapeutics Stock Up 0.5 %

Shares of SpringWorks Therapeutics stock opened at $46.69 on Wednesday. SpringWorks Therapeutics has a 1-year low of $18.00 and a 1-year high of $53.92. The firm’s 50-day moving average price is $47.45 and its two-hundred day moving average price is $38.30.

Insider Transactions at SpringWorks Therapeutics

In other news, insider Daniel Pichl sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $50.10, for a total transaction of $751,500.00. Following the transaction, the insider now directly owns 45,212 shares in the company, valued at $2,265,121.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.61% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have weighed in on SWTX shares. HC Wainwright upped their price objective on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Guggenheim started coverage on shares of SpringWorks Therapeutics in a research note on Monday, February 5th. They set a “buy” rating and a $75.00 price objective on the stock. Wedbush upped their price objective on shares of SpringWorks Therapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Monday, February 26th. Barclays upped their price objective on shares of SpringWorks Therapeutics from $47.00 to $63.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Finally, JPMorgan Chase & Co. upped their price objective on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $68.00.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.